239 related articles for article (PubMed ID: 19069157)
21. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
Mignani R; Cagnoli L
J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
[TBL] [Abstract][Full Text] [Related]
22. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.
Oder D; Liu D; Hu K; Üçeyler N; Salinger T; Müntze J; Lorenz K; Kandolf R; Gröne HJ; Sommer C; Ertl G; Wanner C; Nordbeck P
Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 29018006
[TBL] [Abstract][Full Text] [Related]
23. Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression.
Paliouras C; Aperis G; Lamprianou F; Ntetskas G; Roufas K; Alivanis P
Nefrologia; 2015; 35(6):578-81. PubMed ID: 26384850
[TBL] [Abstract][Full Text] [Related]
24. [Ocular findings in Fabry's disease].
Kuzman T; Juri J; Mrsić M; Jeren-Strujić B; Mandić Z; Sikić J
Acta Med Croatica; 2006; 60(2):163-6. PubMed ID: 16848212
[TBL] [Abstract][Full Text] [Related]
25. [Current status and future prospect of enzyme replacement therapy for Fabry disease].
Ohashi T
Rinsho Shinkeigaku; 2019 Jun; 59(6):335-338. PubMed ID: 31142708
[TBL] [Abstract][Full Text] [Related]
26. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
[TBL] [Abstract][Full Text] [Related]
27. High incidence of thrombosis in Fabry's disease.
Utsumi K; Yamamoto N; Kase R; Takata T; Okumiya T; Saito H; Suzuki T; Uyama E; Sakuraba H
Intern Med; 1997 May; 36(5):327-9. PubMed ID: 9213168
[TBL] [Abstract][Full Text] [Related]
28. Fabry disease female proband with clinical manifestations similar to hypertrophic cardiomyopathy.
Teragaki M; Tanaka A; Akioka K; Lan HT; Nishi Y; Yamano T; Yoshikawa J
Jpn Heart J; 2004 Jul; 45(4):685-9. PubMed ID: 15353880
[TBL] [Abstract][Full Text] [Related]
29. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
30. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.
Schaefer E; Mehta A; Gal A
Acta Paediatr Suppl; 2005 Mar; 94(447):87-92; discussion 79. PubMed ID: 15895718
[TBL] [Abstract][Full Text] [Related]
31. Novel alpha-galactosidase A mutation in a female with recurrent strokes.
Tuttolomondo A; Duro G; Miceli S; Di Raimondo D; Pecoraro R; Serio A; Albeggiani G; Nuzzo D; Iemolo F; Pizzo F; Sciarrino S; Licata G; Pinto A
Clin Biochem; 2012 Nov; 45(16-17):1525-30. PubMed ID: 22820434
[TBL] [Abstract][Full Text] [Related]
32. The Changing Landscape of Fabry Disease.
Svarstad E; Marti HP
Clin J Am Soc Nephrol; 2020 Apr; 15(4):569-576. PubMed ID: 32132142
[No Abstract] [Full Text] [Related]
33. [Neurological manifestations of Fabry disease].
Mendióroz M; Fernández-Cadenas I; Montaner J
Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
[TBL] [Abstract][Full Text] [Related]
34. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
[TBL] [Abstract][Full Text] [Related]
35. [Contribution of genotyping in Fabry's disease].
Froissart R; Piraud M; Maire I
Rev Med Interne; 2010 Dec; 31 Suppl 2():S275-8. PubMed ID: 21211679
[TBL] [Abstract][Full Text] [Related]
36. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
[TBL] [Abstract][Full Text] [Related]
37. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives].
Germain DP
Rev Med Interne; 2000 Dec; 21(12):1086-103. PubMed ID: 11191676
[TBL] [Abstract][Full Text] [Related]
38. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
40. Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson-Fabry disease.
Stamerra CA; De Feo M; Castelli V; d'Angelo M; Cimini A; Grassi D; Ferri C
Eur J Hum Genet; 2021 Feb; 29(2):218-224. PubMed ID: 32948848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
